Among patients with FIGO 2014 Stage III-IVA cervical cancer, treatment with pembrolizumab plus CRT significantly reduced the risk of disease progression or death by 41% compared with placebo plus CRT.
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results